REFRACTORY CLASSIC HODGKIN LYMPHOMA
Clinical trials for REFRACTORY CLASSIC HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY CLASSIC HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY CLASSIC HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple-Drug attack on tough hodgkin lymphoma shows promise in early trial
Disease control OngoingThis study tests a combination of three drugs—ipilimumab, nivolumab, and brentuximab vedotin—in people with Hodgkin lymphoma that has returned or not responded to treatment. The drugs work by helping the immune system attack cancer cells and by delivering a toxin directly to them…
Matched conditions: REFRACTORY CLASSIC HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can an old drug make immunotherapy work again for hodgkin lymphoma?
Disease control OngoingThis early-phase trial tests whether adding an oral chemotherapy drug (CC-486) to the immunotherapy nivolumab can help patients with Hodgkin lymphoma whose cancer no longer responds to PD-1 blockers. About 33 adults will receive the combination to find the safest dose and see if …
Matched conditions: REFRACTORY CLASSIC HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo tackles tough lymphomas
Disease control OngoingThis early-phase trial tests the safety and best dose of combining two drugs—pembrolizumab (Keytruda) and vorinostat (Zolinza)—in people with certain lymphomas that have returned or not responded to treatment. Pembrolizumab helps the immune system attack cancer cells, while vorin…
Matched conditions: REFRACTORY CLASSIC HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 26, 2026 12:46 UTC